75 related articles for article (PubMed ID: 22080880)
1. Cancer stem cell and embryonic development-associated molecules contribute to prognostic significance in ovarian cancer.
Oktem G; Sanci M; Bilir A; Yildirim Y; Kececi SD; Ayla S; Inan S
Int J Gynecol Cancer; 2012 Jan; 22(1):23-9. PubMed ID: 22080880
[TBL] [Abstract][Full Text] [Related]
2. [Expressions of OCT4, Notch1 and DLL4 and their clinical implications in epithelial ovarian cancer].
Yu L; Jiao YJ; Zhou L; Song WQ; Wu SW; Wang DN
Nan Fang Yi Ke Da Xue Xue Bao; 2016 Apr; 37(4):444-450. PubMed ID: 28446394
[TBL] [Abstract][Full Text] [Related]
3. Smoking and risk of ovarian cancer by histological subtypes: an analysis among 300 000 Norwegian women.
Licaj I; Jacobsen BK; Selmer RM; Maskarinec G; Weiderpass E; Gram IT
Br J Cancer; 2017 Jan; 116(2):270-276. PubMed ID: 27959888
[TBL] [Abstract][Full Text] [Related]
4. Neuroendocrine Marker Expression in Primary Non-neuroendocrine Epithelial Tumors of the Ovary: A Study of 551 Cases.
Kendall Bártů M; Němejcová K; Michálková R; Bui QH; Drozenová J; Fabian P; Fadare O; Hausnerová J; Laco J; Matěj R; Méhes G; Šafanda A; Singh N; Škapa P; Špůrková Z; Stolnicu S; Švajdler M; Lax SF; McCluggage WG; Dundr P
Int J Gynecol Pathol; 2024 Mar; 43(2):123-133. PubMed ID: 37406366
[TBL] [Abstract][Full Text] [Related]
5. Synergy of the microRNA Ratio as a Promising Diagnosis Biomarker for Mucinous Borderline and Malignant Ovarian Tumors.
Dolivet E; Gaichies L; Jeanne C; Bazille C; Briand M; Vernon M; Giffard F; Leprêtre F; Poulain L; Denoyelle C; Vigneron N; Fauvet R
Int J Mol Sci; 2023 Nov; 24(21):. PubMed ID: 37958997
[TBL] [Abstract][Full Text] [Related]
6. Infiltrative pattern of invasion is independently associated with shorter survival and desmoplastic stroma markers FAP and THBS2 in mucinous ovarian carcinoma.
Köbel M; Kang EY; Lee S; Terzic T; Karnezis AN; Ghatage P; Woo L; Lee CH; Meagher NS; Ramus SJ; Gorringe KL
Histopathology; 2024 Jun; 84(7):1095-1110. PubMed ID: 38155475
[TBL] [Abstract][Full Text] [Related]
7. EGFR, HLA-G, CD70, c-MET, and NY-ESO1 as potential biomarkers in high grade epithelial ovarian carcinoma.
Vo D; Liu Y; Sood AK; Rezvani K; Jazaeri AA; Liu J
Cancer Biomark; 2024; 39(4):289-298. PubMed ID: 38250760
[TBL] [Abstract][Full Text] [Related]
8. Prognostic Impact of LGR5, Prox1, and Notch1 Biomarkers in Stage II to III Colon Cancer.
Abdelrahman AE; El-Azony A; Elsebai E; Ibrahim HM
Appl Immunohistochem Mol Morphol; 2022 Feb; 30(2):126-135. PubMed ID: 34657081
[TBL] [Abstract][Full Text] [Related]
9. Rare Epithelial Ovarian Cancers: Low Grade Serous and Mucinous Carcinomas.
Craig O; Nigam A; Dall GV; Gorringe K
Cold Spring Harb Perspect Med; 2023 Sep; 13(9):. PubMed ID: 37277207
[TBL] [Abstract][Full Text] [Related]
10. L1-CAM in Mucinous Ovarian Carcinomas and Borderline Tumors: Impact on Tumor Recurrence and Potential Role in Tumor Progression.
Wiedenhoefer R; Schmoeckel E; Grube M; Sulyok M; Pasternak I; Beschorner C; Greif K; Brucker S; Mayr D; Kommoss S; Fend F; Staebler A; Fischer AK
Am J Surg Pathol; 2023 May; 47(5):558-567. PubMed ID: 36852510
[TBL] [Abstract][Full Text] [Related]
11. Investigating the Spatial Distribution of Proliferating Cells in Primary Ovarian Cancers.
Hegazi MAAA; Pasqualini F; Taverna G; Bresalier RS; Chiriva-Internati M; Grizzi F
Discov Med; 2024 Mar; 36(182):632-645. PubMed ID: 38531804
[TBL] [Abstract][Full Text] [Related]
12. Proteomic characterization of epithelial ovarian cancer delineates molecular signatures and therapeutic targets in distinct histological subtypes.
Gong TT; Guo S; Liu FH; Huo YL; Zhang M; Yan S; Zhou HX; Pan X; Wang XY; Xu HL; Kang Y; Li YZ; Qin X; Xiao Q; Huang DH; Li XY; Zhao YY; Zhao XX; Wang YL; Ma XX; Gao S; Zhao YH; Ning SW; Wu QJ
Nat Commun; 2023 Nov; 14(1):7802. PubMed ID: 38016970
[TBL] [Abstract][Full Text] [Related]
13. The molecular origin and taxonomy of mucinous ovarian carcinoma.
Cheasley D; Wakefield MJ; Ryland GL; Allan PE; Alsop K; Amarasinghe KC; Ananda S; Anglesio MS; Au-Yeung G; Böhm M; Bowtell DDL; Brand A; Chenevix-Trench G; Christie M; Chiew YE; Churchman M; DeFazio A; Demeo R; Dudley R; Fairweather N; Fedele CG; Fereday S; Fox SB; Gilks CB; Gourley C; Hacker NF; Hadley AM; Hendley J; Ho GY; Hughes S; Hunstman DG; Hunter SM; Jobling TW; Kalli KR; Kaufmann SH; Kennedy CJ; Köbel M; Le Page C; Li J; Lupat R; McNally OM; McAlpine JN; Mes-Masson AM; Mileshkin L; Provencher DM; Pyman J; Rahimi K; Rowley SM; Salazar C; Samimi G; Saunders H; Semple T; Sharma R; Sharpe AJ; Stephens AN; Thio N; Torres MC; Traficante N; Xing Z; Zethoven M; Antill YC; Scott CL; Campbell IG; Gorringe KL
Nat Commun; 2019 Sep; 10(1):3935. PubMed ID: 31477716
[TBL] [Abstract][Full Text] [Related]
14. Quantitative DNA hypomethylation of ligand Jagged1 and receptor Notch1 signifies occurrence and progression of breast carcinoma.
Cao Y; Li Y; Zhang N; Hu J; Yin L; Pan Z; Li Y; Du X; Zhang W; Li F
Am J Cancer Res; 2015; 5(5):1621-34. PubMed ID: 26175933
[TBL] [Abstract][Full Text] [Related]
15. Editorial: Infiltrative pattern of invasion is independently associated with shorter survival and desmoplastic stroma markers FAP and THBS2 in mucinous ovarian carcinoma.
Parra-Herran C; Dundr P; McCluggage WG
Histopathology; 2024 Jun; 84(7):1092-1094. PubMed ID: 38655820
[No Abstract] [Full Text] [Related]
16. High BMP7 expression is associated with poor prognosis in ovarian cancer.
Vasan R; Yadav J; Aiyappa-Maudsley R; Deen S; Storr SJ; Martin SG
J Cell Mol Med; 2023 Nov; 27(21):3378-3387. PubMed ID: 37688374
[TBL] [Abstract][Full Text] [Related]
17. Pre-operative plasma VEGF-C levels portend recurrence in epithelial ovarian cancer patients and is a bankable prognostic marker even in the initial assessment of a patient.
Bhaskari J; Bhagat R; Shilpa V; Premalata CS; Krishnamoorthy L
J Ovarian Res; 2024 Apr; 17(1):77. PubMed ID: 38594780
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of Sialyl-Lactotetra as a Marker for Epithelial Ovarian Tumors.
Barone A; Linder A; Mateoiu C; Köster Larsen R; Blixt O; Teneberg S; Sundfeldt K
Front Oncol; 2020; 10():561888. PubMed ID: 33072588
[TBL] [Abstract][Full Text] [Related]
19. Intracystic endometrioid borderline tumor.
El Hajj H; Narducci F; McCluggage G; Pasquesoone C
Int J Gynecol Cancer; 2023 Oct; 33(10):1663-1665. PubMed ID: 37543373
[No Abstract] [Full Text] [Related]
20. Metallothionein - immunohistochemical cancer biomarker: a meta-analysis.
Gumulec J; Raudenska M; Adam V; Kizek R; Masarik M
PLoS One; 2014; 9(1):e85346. PubMed ID: 24416395
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
